Maravai Lifesciences Holdings Inc (MRVI)

$7.66

-0.24

(-3.04%)▲

Market is closed - opens 7 PM, 04 Oct 2024

Performance

  • $7.61
    $7.80
    $7.66
    downward going graph

    0.72%

    Downside

    Day's Volatility :2.5%

    Upside

    1.79%

    downward going graph
  • $4.52
    $11.56
    $7.66
    downward going graph

    40.99%

    Downside

    52 Weeks Volatility :60.88%

    Upside

    33.71%

    downward going graph

Returns

PeriodMaravai Lifesciences Holdings IncSector (Health Care)Index (Russel 2000)
3 Months
18.88%
7.5%
0.0%
6 Months
-3.48%
6.9%
0.0%
1 Year
-15.81%
20.9%
0.0%
3 Years
-80.57%
21.0%
-21.1%

Highlights

Market Capitalization
2.1B
Book Value
$3.09
Earnings Per Share (EPS)
-1.0
Wall Street Target Price
11.27
Profit Margin
-47.41%
Operating Margin TTM
-14.59%
Return On Assets TTM
-1.47%
Return On Equity TTM
-19.39%
Revenue TTM
278.6M
Revenue Per Share TTM
2.09
Quarterly Revenue Growth YOY
6.5%
Gross Profit TTM
714.0M
EBITDA
2.1M
Diluted Eps TTM
-1.0
Quarterly Earnings Growth YOY
-0.33
EPS Estimate Current Year
-0.03
EPS Estimate Next Year
0.02
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    78%Buy
    21%Hold
    0
    0%Sell
Based on 19 Wall street analysts offering stock ratings for Maravai Lifesciences Holdings Inc(by analysts ranked 0 to 5 stars)
Based on 19 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
14
14
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 47.13%

Current $7.66
Target $11.27

Company Financials

FY18Y/Y Change
Revenue
123.8M
-
Net Income
-17.7M
-
Net Profit Margin
-14.32%
-
FY19Y/Y Change
Revenue
143.1M
↑ 15.59%
Net Income
-5.2M
↓ 70.67%
Net Profit Margin
-3.63%
↑ 10.69%
FY20Y/Y Change
Revenue
284.1M
↑ 98.48%
Net Income
76.9M
↓ 1578.33%
Net Profit Margin
27.06%
↑ 30.69%
FY21Y/Y Change
Revenue
799.2M
↑ 181.33%
Net Income
469.3M
↑ 510.3%
Net Profit Margin
58.71%
↑ 31.65%
FY22Y/Y Change
Revenue
883.0M
↑ 10.48%
Net Income
490.7M
↑ 4.56%
Net Profit Margin
55.57%
↓ 3.14%
FY23Y/Y Change
Revenue
288.9M
↓ 67.28%
Net Income
-119.0M
↓ 124.26%
Net Profit Margin
-41.19%
↓ 96.76%
Q1 FY23Q/Q Change
Revenue
79.0M
↓ 61.4%
Net Income
-1.3M
↓ 101.54%
Net Profit Margin
-1.71%
↓ 44.42%
Q2 FY23Q/Q Change
Revenue
68.9M
↓ 12.79%
Net Income
-6.5M
↑ 385.24%
Net Profit Margin
-9.49%
↓ 7.78%
Q3 FY23Q/Q Change
Revenue
66.9M
↓ 2.97%
Net Income
-6.5M
↓ 1.21%
Net Profit Margin
-9.66%
↓ 0.17%
Q4 FY23Q/Q Change
Revenue
74.1M
↑ 10.88%
Net Income
-106.0M
↑ 1539.72%
Net Profit Margin
-142.92%
↓ 133.26%
Q1 FY24Q/Q Change
Revenue
64.2M
↓ 13.44%
Net Income
-12.1M
↓ 88.6%
Net Profit Margin
-18.82%
↑ 124.1%
Q2 FY24Q/Q Change
Revenue
73.4M
↑ 14.37%
Net Income
-7.6M
↓ 37.2%
Net Profit Margin
-10.33%
↑ 8.49%
FY18Y/Y Change
Total Assets
539.7M
-
Total Liabilities
391.7M
-
FY19Y/Y Change
Total Assets
577.8M
↑ 7.06%
Total Liabilities
433.2M
↑ 10.6%
FY20Y/Y Change
Total Assets
1.3B
↑ 119.92%
Total Liabilities
1.1B
↑ 157.62%
FY21Y/Y Change
Total Assets
1.9B
↑ 50.96%
Total Liabilities
1.4B
↑ 23.03%
FY22Y/Y Change
Total Assets
2.3B
↑ 18.98%
Total Liabilities
1.4B
↑ 0.3%
FY23Y/Y Change
Total Assets
1.5B
↓ 34.83%
Total Liabilities
697.6M
↓ 49.34%
Q1 FY23Q/Q Change
Total Assets
2.3B
↑ 1.45%
Total Liabilities
1.4B
↑ 2.74%
Q2 FY23Q/Q Change
Total Assets
2.3B
↓ 2.2%
Total Liabilities
1.4B
↓ 3.39%
Q3 FY23Q/Q Change
Total Assets
2.3B
↑ 0.14%
Total Liabilities
1.4B
↑ 0.62%
Q4 FY23Q/Q Change
Total Assets
1.5B
↓ 34.4%
Total Liabilities
697.6M
↓ 49.28%
Q1 FY24Q/Q Change
Total Assets
1.4B
↓ 2.88%
Total Liabilities
667.3M
↓ 4.35%
Q2 FY24Q/Q Change
Total Assets
1.4B
↑ 0.21%
Total Liabilities
671.2M
↑ 0.59%
FY18Y/Y Change
Operating Cash Flow
-186.0K
-
Investing Cash Flow
-3.5M
-
Financing Cash Flow
-9.2M
-
FY19Y/Y Change
Operating Cash Flow
24.1M
↓ 13065.05%
Investing Cash Flow
-17.1M
↑ 396.9%
Financing Cash Flow
-4.2M
↓ 54.54%
FY20Y/Y Change
Operating Cash Flow
152.2M
↑ 531.09%
Investing Cash Flow
6.1M
↓ 135.39%
Financing Cash Flow
53.2M
↓ 1376.99%
FY21Y/Y Change
Operating Cash Flow
368.6M
↑ 142.18%
Investing Cash Flow
105.7M
↑ 1641.18%
Financing Cash Flow
-159.0M
↓ 398.9%
FY22Y/Y Change
Operating Cash Flow
536.0M
↑ 45.42%
Investing Cash Flow
-267.6M
↓ 353.29%
Financing Cash Flow
-187.5M
↑ 17.89%
Q1 FY23Q/Q Change
Operating Cash Flow
85.1M
↓ 14.36%
Investing Cash Flow
-69.7M
↑ 276.51%
Financing Cash Flow
-19.2M
↓ 70.95%
Q2 FY23Q/Q Change
Operating Cash Flow
19.2M
↓ 77.44%
Investing Cash Flow
-24.2M
↓ 65.36%
Financing Cash Flow
-43.1M
↑ 124.55%

Technicals Summary

Sell

Neutral

Buy

Maravai Lifesciences Holdings Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Maravai Lifesciences Holdings Inc
Maravai Lifesciences Holdings Inc
-4.81%
-3.48%
-15.81%
-80.57%
-78.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-10.06%
10.55%
30.05%
89.27%
274.48%
Novo Nordisk A/s
Novo Nordisk A/s
-12.62%
-6.24%
35.65%
145.66%
372.59%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.37%
82.34%
59.06%
41.03%
258.58%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.23%
13.76%
34.75%
162.16%
172.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Maravai Lifesciences Holdings Inc
Maravai Lifesciences Holdings Inc
45.97
NA
NA
-0.03
-0.19
-0.01
NA
3.09
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
27.85
27.85
1.43
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.39
40.39
1.82
3.45
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.56
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Maravai Lifesciences Holdings Inc
Maravai Lifesciences Holdings Inc
Buy
$2.1B
-78.14%
45.97
-47.41%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.9B
274.48%
27.85
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$531.4B
372.59%
40.39
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$35.3B
258.58%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.0B
172.77%
32.84
-4.74%

Insights on Maravai Lifesciences Holdings Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 64.17M → 73.4M (in $), with an average increase of 12.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -105.95M → -7.58M (in $), with an average increase of 418.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.1% return, outperforming this stock by 74.9%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.7% return, outperforming this stock by 123.5%

Institutional Holdings

  • GTCR LLC

    14.23%

  • 12 West Capital Management LP

    9.33%

  • Vanguard Group Inc

    7.59%

  • BlackRock Inc

    6.87%

  • BRAIDWELL LP

    6.38%

  • Millennium Management LLC

    4.22%

Company Information

maravai lifesciences catalyzes the growth of successful, entrepreneurial life science companies by providing expertise, capital, processes and systems so that they can continue to serve scientists who are striving to improve human health. current maravai lifesciences portfolio companies provide enabling tools and services in the life sciences research and bioproduction industries that accelerate breakthrough discoveries in areas such as genomics, proteomics, and biotherapeutic development. maravai lifesciences was formed in march 2014 through a partnership with gtcr, a leading private equity firm. our mission is to build a transformative life sciences reagents company by acquiring outstanding businesses and accelerating their growth. since our founding, we have acquired four companies, each a leader in its market segment. vector laboratories has led the market for labeling and detection products used by researchers in immunohistochemistry, immunofluorescence and related techniques. tri

Organization
Maravai Lifesciences Holdings Inc
Employees
580
CEO
Mr. Carl W. Hull
Industry
Commercial Services

Discover More

FAQs